



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspio.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/075,249	02/15/2002	Emanuela Mundo	10822-21	8612
1059	7590 09/20/2005		EXAMINER	
BERESKIN AND PARR			BRANNOCK, MICHAEL T	
40 KING ST BOX 401	REET WEST		ART UNIT	PAPER NUMBER
TORONTO, ON M5H 3Y2			1649	
CANADA			DATE MAILED: 09/20/2009	5

Please find below and/or attached an Office communication concerning this application or proceeding.



COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, DC 20231 WASHINGTON, DC 20231

APPLICATION NO. 10075249	FILING DATE	FIRST NAMED INVENTOR Mundo		ATTORNEY DOCKET NO.	
				EXAMINER	
			Mid	Michael Brannock	
	•	·	ART UNIT	PAPER	
			1649	090705	
			DATE MAILED		

Please find below and/or attached an Office communication concerning this application or proceeding.

## **Commissioner of Patents**

Applicant's timely response (5/23/05) to the prior office action (2/24/05) is noted. Applicant's arguments will be held in abeyance until the sequence rules issue is obviated. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures, see Figure 1. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the one month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Brannock, Ph.D., whose telephone number is (571) 272-0869. The examiner can normally be reached on Monday through Friday from 10:00 AM to 4:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, Ph.D., can be reached at (571) 272-0867. Official papers filed by fax should be directed to 571-273-8300. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

M

ELIZABETH KEMMERER PRIMARY EXAMINER

	Application No.	Applicant(s)				
Notice to Comply	10075249	Mundo				
Notice to Comply	Examiner	Art Unit				
	Michael Brannock	1649				
NOTICE TO COMPLY WITH REQUESTIONS OF THE SECOND AND ADDRESS OF THE SECOND AD						
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES						
Applicant must file the items indicated below is attached to avoid abandonment under 3 provisions of 37 CFR 1.136(a)).						
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):						
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).						
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).						
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).						
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."						
and/or unreadable as indicated on the	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).					
6. The paper copy of the "Sequence L" "Sequence Listing" as required by 37 (		mputer readable fr	rom of the			
7. Other:						
Applicant Must Provide:  ☑ An initial or substitute computer reada	ble form (CRF) copy of the "Sec	juence Listing".				
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.						
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).						
For questions regarding compliance	e to these requirements, p	lease contact:				
For Rules Interpretation, call (571) 272-2510						
For CRF Submission Help, call (571) 272-2501/2583						
PatentIn Software Program Suppor Technical Assistance		200				
To Purchase Patentin Software						

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY